T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy

Cited by (156)

Items 101–156 of 156

1. CRPMKB: a knowledge base of cancer risk prediction models for systematic comparison and personalized applications
   Shumin Ren, Yanwen Jin, Yalan Chen, Bairong Shen · 2021 · Bioinformatics
2. Why Immunotherapy Fails in Multiple Myeloma
   Luis Gerardo Rodríguez‐Lobato, Aina Oliver‐Caldés, David Fernando Moreno, Carlos Fernández de Larrea, Joan Bladé · 2020 · Hemato
3. Fine tuning towards the next generation of engineered T cells
   Thi Tham Nguyen, Patrick Ho, Sarah Staudt, Céline Grégoire, Kai Ziegler-Martin, Mégane Jassin, Alix Block, Michael Hudecek, Jan Joseph Melenhorst, Jo Caers et al. · 2025 · Nature Biomedical Engineering
4. CAR T cells in solid tumors and metastasis: paving the way forward
   Camilla Sirini, Laura Rossi, Marta Angiola Moresco, Monica Casucci · 2024 · Cancer and Metastasis Reviews
5. Car-T Cell Therapy: Current Advances and Future Research Possibilities
   Manal Mohamed Elsayed Ahmed · 2021 · Journal of Scientific Research in Medical and Biological Sciences
6. Alignment of practices for data harmonization across multi-center cell therapy trials: a report from the Consortium for Pediatric Cellular Immunotherapy
   Hisham Abdel‐Azim, Hema Dave, Kimberly Rae Jordan, Stephanie D. Rawlings-Rhea, Annie Luong, Ashley Lauren Wilson · 2021 · Cytotherapy
7. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies
   Robert D. Schwab, Darel Martinez Bedoya, Tiffany R. King-Peoples, Bruce L. Levine, Avery D. Posey · 2019 · Methods in molecular biology
8. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions
   Adriano Salaroli, Chloé Spilleboudt, D Bron, Philippe Lewalle · 2020 · Current Opinion in Oncology
9. Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation
   Aileen W. Li, Jessica D. Briones, Jia Lü, Quinn Walker, Rowena Martinez, Hajime Hiraragi, Bijan A. Boldajipour, Purnima Desai Sundar, Shobha Potluri, Gary Lee et al. · 2024 · Scientific Reports
10. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma
    Baojun Wei, Meng Yu, Jihang Yao, Mingzhe Jiang, Jun An, Jieping Yang, Jiaxing Lin, Yongkang Zhao, Yuyan Zhu · 2021 · Frontiers in Immunology
11. Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes
    Anže Smole · 2022 · Radiology and Oncology
12. Acute Conditioning of Antigen-Expanded CD8+ T Cells via the GSK3β-mTORC Axis Differentially Dictates Their Immediate and Distal Responses after Antigen Rechallenge
    Pavla Táborská, Dmitry Stakheev, Hana Svobodová, Zuzana Ozaniak Strizova, Jiřina Bartůňková, Daniel Smrž · 2020 · Cancers
13. Recombinant Human Cyclophilin A in Combination with Adoptive T-cell Therapy Improves the Efficacy of Cancer Immunotherapy in Experimental Models in vivo
    Anastasiia A. Kalinina, Dmitry B. Kazansky, Ludmila M. Khromykh · 2023 · Biochemistry (Moscow)
14. The promise of immunotherapeutic strategies to advance cancer treatment in pet dogs
    Jordan Hampel, Natrine Cheuk, Matheus Moreno P. Barbosa, Timothy M. Fan · 2024 · Journal of the American Veterinary Medical Association
15. Navigating the Fas lane to improved cellular therapy for cancer
    Madhav V. Dhodapkar · 2019 · Journal of Clinical Investigation
16. Co-editing of NKG2A and FAS increases long-term cytotoxic capacity and persistence of CAR NK cells
    Juliane Mietz, Lukas Egli, Meike Misiune, Arianna Picozzi, Nicolò Coianiz, Danielle Thompson, Marianna Ponzo, Alisson Charmey, Beat C. Bornhauser, Chiara Francesca Magnani et al. · 2026 · Molecular Therapy Oncology
17. Next generation CAR-T cells to tackle solid tumors
    Teresa R. Abreu, Ana Godinho‐Santos, Ana Teresa Amaral, Artur Augusto Paiva, João Nuno Moreira, J. Ricardo M. Gonçalves · 2026 · Journal of Controlled Release
18. An in vivo CRISPR screen unveils promising target genes to improve CAR-T cell efficacy in a solid tumor model
    Mattia Fumagalli, Dongjie An, Luca Simula, Camille Combe, Lisa Aziez, Yannick Simoni, Marie‐Clotilde Alves‐Guerra, Andrea Valentini, Maude Marchais, Anaïs Vermare et al. · 2026 · Molecular Therapy
19. The Fas/FasL pathway as a target for enhancing anticancer adoptive cell therapy
    Greta Volpedo, Thalia Pacheco‐Fernández, Marianna de Carvalho Clímaco, Abhay R. Satoskar · 2021 · Elsevier eBooks
20. Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells
    Grace Min Yi Tan, Aarati Poudel, Seyed Mohammad Ali Hosseini Rad, Alexander Donald McLellan · 2022 · Cancers
21. From mice to men: An assessment of preclinical model systems for the study of vitiligo
    Wei Wu, Xinju Wang, Kaiqiao He, Chunying Li, Shuli Li · 2024 · Clinical Immunology
22. LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling
    Arya Afsahi, Christopher M. Silvestri, Allyson E. Moore, Carly F. Graham, Kaylyn Bacchiochi, Martine St-Jean, Christopher L. Baker, Robert G. Korneluk, Shawn T. Beug, Eric Charles LaCasse et al. · 2023 · Frontiers in Immunology
23. Adenine base editor for knockout of proteins: A practical guide from design to analysis with updated MultiEditRbatch
    Eaton, Ella J., Wick, Bryce J., Chacón, Jeremy S., Wang, Amy J., Kluesner, Mitchell, Barnes, Jackson T., Kar, Bibekananda, Wang, Minjing, Johnson, Matthew J., Skeate, Joseph G. et al. · 2026 · Molecular Therapy Nucleic Acids
24. DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies
    Maria Letizia Giardino Torchia, Gordon E. Moody · 2023 · Frontiers in Immunology
25. Perspectives d’évolution et d’utilisation des cellules CAR-T
    Steve Genebrier, Karin Tarte · 2021 · Bulletin du Cancer
26. Novel Strategies to Improve CAR-T Cells in Solid Tumors: Mini Review
    Manal Mohamed Elsayed Ahmed · 2022 · Journal of Scientific Research in Medical and Biological Sciences
27. Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits
    Theodore L. Roth, P. Jonathan Li, Jasper Friedrich Nies, Ruby Yu, Michelle Ly Thai Nguyen, Youjin Lee, Ryan Apathy, Anna Truong, Joseph B. Hiatt, David Wu et al. · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
28. A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures
    Corey Smith, Vijayendra Dasari, Sriganesh Srihari, Laëtitia Le Texier, Matthew Solomon, Archana Panikkar, Thuy T. Le, George R. Ambalathingal, Jyothy Raju, Sweera Rehan et al. · 2026 · Nature Communications
29. Innate lymphoid cells integrate sensing and plasticity to control fungal infections
    Irina Tsymala, Philipp Penninger, Filomena Nogueira, Sabrina Jenull, Trinh Phan-Canh, Helena Brezovec, Magdalena Teufl, Sara Miranda, Wilfried Ellmeier, Nicole Boucheron et al. · 2026 · Cell Reports
30. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors
    Guangxun Yuan, Mengke Ye, Yixi Zhang, Xun Zeng · 2024 · Medical Oncology
31. 176 Evaluating the safety of tumor treating fields (TTFields) application to the torso – in vivo studies
    Shiri Davidi, Roni Blat, Mijal Munster, Anna Shteingauz, Shay Cahal, Moshe Giladi, Uri Weinberg, Yoram Palti, Moshe Giladi · 2020 · Regular and Young Investigator Award Abstracts
32. Akt Fas to Quell Aberrant T Cell Differentiation and Death in Covid-19
    Anthony Joseph Leonardi · 2020
33. Leucine zipper-based sorting system enables generation of multi-functional CAR T cells
    Scott E. James, Sophia Chen, Brandon D. Ng, Jacob S. Fischman, Lorenz Jahn, Alexander P. Boardman, Adhithi Rajagopalan, Harold Kunal Elias, Alyssa Massa, Dylan Manuele et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
34. An in vivo CRISPR screen unveils top target genes to improve CAR-T cell efficacy in a solid tumor model
    Mattia Fumagalli, Dongjie An, Luca Simula, Camille Combe, Lisa Aziez, Yannick Simoni, Marie‐Clotilde Alves‐Guerra, Andrea Valentini, Maude Marchais, Anaïs Vermare et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
35. CAR T-Cell Therapy for CNS Malignancies
    Khaled S. Sanber, Sujith K. Joseph, Nabil M. Ahmed · 2019 · Elsevier eBooks
36. 174 An ex vivo tumoroid model of fresh patient tumors (3D-ACT) to assess efficacy of cellular therapy in immuno-oncology
    Stephen Iwanowycz, Jared C. Ehrhart, Mibel M. Pabon, Tina Pastoor, Jenny M. Kreahling, Soner Altiok · 2020 · Regular and Young Investigator Award Abstracts
37. Tumor MHCII immunity requires in situ antigen presentation by cancer-associated fibroblasts.
    Dimitra Kerdidani, Emmanouil Aerakis, Kleio‐Maria Verrou, Petros Stamoulis, Katerina Goudevenou, Alejandro Prados, Christos Tzaferis, Ioannis N. Vamvakaris, Evangelos Kaniaris, Κonstantinos Vachlas et al. · 2021 · Research Square
38. The Evolution and Recent Progress in the Field of Synthetic Immunology
    Amaan Rather, Pavithran T. Ravindran · 2021 · Journal of Student Research
39. Immunotherapies and their moderation
    Hymie Anisman, Alexander W. Kusnecov · 2022 · Elsevier eBooks
40. The Potential Success and Setbacks of CAR-T Cell Therapy
    Angel He Wang · 2022 · American Journal of Biomedical Science & Research
41. Data from Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy
    Dylan J. Drakes, Sarwish Rafiq, Terence J. Purdon, Andrea V. Lopez, Smita S. Chandran, Christopher Austin Klebanoff, Renier J. Brentjens · 2023
42. Characterization of the Cytotoxic T lymphocytes Acute Response Following Continuous Moderate Intensity and High Intensity Interval Exercise in Metastatic Cancer Patients Undergoing Chemotherapy
    Hugo Parent-Roberge, Adeline Fontvieille, Laurence Poirier, Lee‐Hwa Tai, Michel Pavic, Tamàs Fülöp, Éléonor Riesco · 2023
43. Recombinant human cyclophilin A in combination with adoptive T cell therapy improves the efficacy of cancer immunotherapy in experimental models in vivot;
    Anastasiia A. Kalinina, Dmitry B. Kazansky, Ludmila M. Khromykh · 2023 · Biochemistry (Moscow)
44. Mechanisms of resistance to immunotherapy
    Bernadette Blauensteiner, Theresa Lentner, Verónica Moreno‐Viedma · 2024 · Elsevier eBooks
45. A PI3Kδ-Foxo1-FasL signaling amplification loop rewires CD4 + T helper cell signaling, differentiation and epigenetic remodeling
    Dominic P. Golec, Pedro Henrique Gazzinelli-Guimarães, Daniel Chauss, Hiroyuki Nagashima, Kang Yu, Tom Hill, Luis Alberto Nivelo, Jennifer Leigh Cannons, Jillian Perry, Ilin V. Joshi et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
46. Apoptosis and Cancer Immunotherapy: Current Mechanisms and Emerging Strategies
    Satyajit Halder, Kuladip Jana · 2024 · Springer eBooks
47. Installation of dominant-negative mutations in FAS and TGFβR2 via base editing in primary T cells
    Bryce J. Wick, Mitchell G. Kluesner, Nicholas J. Slipek, Joseph G. Skeate, Ethan M. Niemeyer, Beau R. Webber, Branden S. Moriarity · 2025 · Molecular Therapy Oncology
48. Additional file 1 of Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
    Zhang, Yunlin, Ruchi P. Patel, Kim, Ki Hyun, Hyungwoo Cho, Jo, Jae-Cheol, Seong Hyun Jeong, Sung Young Oh, Choi, Yoon Seok, Kim, Sung Hyun, Lee, Ji Hyun et al. · 2024 · Figshare
49. Additional file 2 of Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study
    Zhang, Yunlin, Ruchi P. Patel, Kim, Ki Hyun, Hyungwoo Cho, Jo, Jae-Cheol, Seong Hyun Jeong, Sung Young Oh, Choi, Yoon Seok, Kim, Sung Hyun, Lee, Ji Hyun et al. · 2024 · Figshare
50. A Membrane-Proximal CD19–Targeted CAR T Cell With Rapid Binding Kinetics Overcomes Resistance In Relapsed B-Cell Lymphoma
    Daniel I. Ferrari, Ingrid K. Alvarez, Maria Lei Zhang, Lina Wilson, Rebecca Y. Ramirez · 2024 · Asian journal of Current Research in Clinical Cancer
51. Defining the differential contributions of CD4+ and CD8+ T cells to CAR T cell therapy against B cell malignancies
    Morgane Boulch · 2022 · theses.fr (ABES)
52. Fusion protein-mediated costimulation in engineered T cells: from intrinsic signaling to tumor microenvironment rewiring
    Ryma Toumi, Simonne Guenette, Shannon K. Oda · 2026 · Frontiers in Immunology
53. The acute response of cytotoxic T cells following work-matched continuous moderate-intensity and high-intensity interval exercise in metastatic cancer patients undergoing chemotherapy: a pilot study
    Hugo Parent-Roberge, Adeline Fontvieille, Laurence Poirier, Lee‐Hwa Tai, Michel Pavic, Tamas Fulop, Éléonor Riesco · 2026 · Applied Physiology, Nutrition, and Metabolism
54. A Next-Generation CD19 CAR T Cell Therapy Targeting a Membrane-Proximal Epitope Overcomes Resistance in B-Cell Non-Hodgkin Lymphoma
    Zsolt Kovács, Katalin Szabo, Gabor Nagy, Eszter Toth · 2026 · Archive of International Journal of Cancer and Allied Science
55. Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases
    Zhuolin Fan, Xu Zheng, Chuan Jin, Jing Zhang, Ningqiang Gong, Xuexin Li · 2026 · Signal Transduction and Targeted Therapy
56. Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion
    Yue-Song Bai, Jin-Tao Qin, Zong-Jun Dai, R. Yan, Yong Yang, Wen-Guang Wang · 2026 · Exploration